Extended Follow Up of the Mainritsan 2 Study. Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab: a Placebo- Controlled Randomized Trial
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 07 Mar 2018
At a glance
- Drugs Rituximab (Primary)
- Indications Microscopic polyangiitis; Wegener's granulomatosis
- Focus Therapeutic Use
- Acronyms MAINRITSAN3
- 01 Mar 2018 Planned End Date changed from 1 Jan 2019 to 1 Sep 2019.
- 01 Mar 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Sep 2018.
- 14 Sep 2016 Status changed from recruiting to active, no longer recruiting.